82 FR 56834 - National Institute on Drug Abuse; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 229 (November 30, 2017)

Page Range		56834-56835
FR Document		2017-25787

Federal Register, Volume 82 Issue 229 (Thursday, November 30, 2017)

[Federal Register Volume 82, Number 229 (Thursday, November 30, 2017)]
[Notices]
[Pages 56834-56835]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-25787]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant

[[Page 56835]]

applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research 
(R21).
    Date: December 15, 2017.
    Time: 3:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: November 24, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-25787 Filed 11-29-17; 8:45 am]
 BILLING CODE 4140-01-P

56834 Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Notices

Officer, Indian Health Service, 5600 collections may still be eligible for Name of Committee: National Cancer
Fishers Lane, Rockville, MD 20857. submission for other generic Institute Special Emphasis Panel; NCI SPORE
• Phone: 301–443–4750. mechanisms that are designed to yield I Review.
Date: January 25–26, 2018.
• Email: Evonne.Bennett-Barnes@ quantitative results. Below are the IHS
Time: 4:00 p.m. to 5:00 p.m.
ihs.gov. projected average estimates for the next Agenda: To review and evaluate grant
• Fax: 301–443–4750. three years: 1 applications.
SUPPLEMENTARY INFORMATION: Title: Current Actions: Extension of Place: Cambria Hotel & Suite Rockville, 1
OMB Control No. 0917–0036, Fast Track approval for a collection of information. Helen Heneghan Way, Rockville, MD 20850.
Generic Clearance for the Collection of Type of Review: Extension. Contact Person: David G. Ransom, Ph.D.,
Qualitative Feedback on Agency Service Affected Public: Individuals and Scientific Review Officer, Research Program
Delivery: IHS Customer Service households, businesses and Review Branch, Division of Extramural
organizations, and Tribal Government. Activities, National Cancer Institute, NIH,
Satisfaction and Similar Surveys. 9609 Medical Center Drive, Room 7W124,
Average expected annual number of
Abstract: The IHS will be engaging in Bethesda, MD 20892–9750, 240–276–6351,
activities: 100.
information collection activities that Respondents: 105,000. david.ransom@nih.gov.
will garner qualitative customer and Annual responses: 105,000. Name of Committee: National Cancer
stakeholder feedback in an efficient, Frequency of response: Once per Institute Initial Review Group; Subcommittee
timely manner, in accordance with the request. F—Institutional Training and Education.
Administration’s commitment to Average minutes per response: 10. Date: February 26–27, 2018.
improving service delivery within Burden hours: 17,500. Time: 7:00 p.m. to 4:00 p.m.
Federal Agencies. Qualitative feedback An agency may not conduct or Agenda: To review and evaluate grant
is information that provides useful applications.
sponsor, and a person is not required to
Place: Bethesda Marriott Suites, 6711
insights on perceptions and opinions, respond to, a collection of information Democracy Boulevard, Bethesda, MD 20817.
but are not statistical surveys that yield unless it displays a currently valid OMB Contact Person: Timothy C. Meeker, MD,
quantitative results that can be control number. Scientific Review Officer, Resources and
generalized to the population of study. Dated: November 17, 2017. Training Review Branch, Division of
This feedback will provide insight into Extramural Activities, National Cancer
Michael D. Weahkee,
customer or stakeholder perceptions, Institute, NIH, 9609 Medical Center Drive,
Assistant Surgeon General, U.S. Public Health Room 7W642, Bethesda, MD 20892–9750,
opinions, experiences and expectations,
Service, Acting Director, Indian Health 240–276–6464, meekert@mail.nih.gov.
and provide an early warning of issues Service.
with service. Also, the collection of (Catalogue of Federal Domestic Assistance
[FR Doc. 2017–25815 Filed 11–29–17; 8:45 am]
qualitative feedback will assist IHS to Program Nos. 93.392, Cancer Construction;
BILLING CODE 4165–16–P 93.393, Cancer Cause and Prevention
focus its attention on areas where
communication, training, or changes in Research; 93.394, Cancer Detection and
operations might improve delivery of Diagnosis Research; 93.395, Cancer
DEPARTMENT OF HEALTH AND Treatment Research; 93.396, Cancer Biology
products or services. These collections HUMAN SERVICES Research; 93.397, Cancer Centers Support;
will allow for ongoing, collaborative and 93.398, Cancer Research Manpower; 93.399,
actionable communications between the National Institutes of Health Cancer Control, National Institutes of Health,
Agency and its customers and HHS)
stakeholders. Furthermore, the National Cancer Institute; Notice of
collection activity will allow feedback Closed Meetings Dated: November 24, 2017.
to contribute directly to the Melanie J. Pantoja,
Pursuant to section 10(d) of the
improvement of program management. Program Analyst, Office of Federal Advisory
Federal Advisory Committee Act, as
Feedback or information collected Committee Policy.
amended, notice is hereby given of the
under this generic clearance will [FR Doc. 2017–25785 Filed 11–29–17; 8:45 am]
following meetings.
provide useful information, but it will BILLING CODE 4140–01–P
The meetings will be closed to the
not yield data that can be generalized to
public in accordance with the
the overall population. This type of
provisions set forth in sections
generic clearance for qualitative DEPARTMENT OF HEALTH AND
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
collection will not be used for HUMAN SERVICES
as amended. The grant applications and
quantitative information collections that
the discussions could disclose National Institutes of Health
are designed to yield reliably actionable
confidential trade secrets or commercial
results, such as monitoring trends over
property such as patentable material, National Institute on Drug Abuse;
time or documenting program
and personal information concerning Notice of Closed Meeting
performance. Such data uses require
individuals associated with the grant
more rigorous designs that address: the Pursuant to section 10(d) of the
applications, the disclosure of which
target population to which Federal Advisory Committee Act, as
would constitute a clearly unwarranted
generalizations will be made, sampling amended, notice is hereby given of the
invasion of personal privacy.
frame, sample design (including following meeting.
stratification and clustering), precision 1 The 60-day notice included the following The meeting will be closed to the
requirements or power calculations that estimate of the aggregate burden hours for this public in accordance with the
justify the proposed sample size, the generic clearance for IHS federal-wide: provisions set forth in sections
daltland on DSKBBV9HB2PROD with NOTICES

expected response rate, methods for Average expected annual number of activities: 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
assessing potential non-response bias, 100. as amended. The grant applications and
Average number of respondents per activity:
protocols for data collection, and any 1,050.
the discussions could disclose
testing procedures that were or will be Annual responses: 105,000. confidential trade secrets or commercial
undertaken prior fielding the study. Frequency of response: Once per request. property such as patentable material,
Depending on the degree of influence Average minutes per response: 10. and personal information concerning
the results are likely to have, such Burden hours: 17,500. individuals associated with the grant

VerDate Sep<11>2014 18:35 Nov 29, 2017 Jkt 244001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\30NON1.SGM 30NON1

Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Notices 56835

applications, the disclosure of which Scientific Review, National Institutes of Diseases, 5601 Fishers Lane, Rm 4F50
would constitute a clearly unwarranted Health, 6701 Rockledge Drive, Room 4176, Bethesda, MD 20892, 301–496–7291,
invasion of personal privacy. MSC 7806, Bethesda, MD 20892, 301–435– fentonm@niaid.nih.gov.
1728, radtkem@csr.nih.gov. Name of Committee: National Advisory
Name of Committee: National Institute on Allergy and Infectious Diseases Council;
Drug Abuse Special Emphasis Panel; (Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine; Allergy, Immunology and Transplantation
Mechanism for Time-Sensitive Drug Abuse Subcommittee.
Research (R21). 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844, Date: January 29, 2018.
Date: December 15, 2017. Closed: 8:30 a.m. to 10:15 a.m.
Time: 3:00 p.m. to 5:00 p.m. 93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS) Agenda: To review and evaluate grant
Agenda: To review and evaluate grant applications.
applications. Dated: November 24, 2017. Place: National Institutes of Health,
Place: National Institutes of Health, Natasha M. Copeland, Natcher Building, Conference Room D, 45
Neuroscience Center, 6001 Executive Center Drive, Bethesda, MD 20892.
Program Analyst, Office of Federal Advisory
Boulevard, Rockville, MD 20852 (Telephone Open: 1:00 p.m. to adjournment.
Committee Policy.
Conference Call). Agenda: Reports from the Division Director
Contact Person: Ivan K. Navarro, Ph.D., [FR Doc. 2017–25784 Filed 11–29–17; 8:45 am]
and other staff.
Scientific Review Officer, Office of BILLING CODE 4140–01–P Place: National Institutes of Health,
Extramural Policy and Review, Division of Natcher Building, Conference Room D, 45
Extramural Research, National Institute on Center Drive, Bethesda, MD 20892.
Drug Abuse, NIH, DHHS, 6001 Executive DEPARTMENT OF HEALTH AND Contact Person: Matthew J. Fenton, Ph.D.,
Boulevard, Room 4242, MSC 9550, Bethesda, HUMAN SERVICES Director, Division of Extramural Activities,
MD 20892, 301–827–5833, ivan.navarro@ National Institute of Allergy and Infectious
nih.gov. National Institutes of Health Diseases, 5601 Fishers Lane, Rm 4F50,
(Catalogue of Federal Domestic Assistance Bethesda, MD 20892, 301–496–7291,
Program Nos.: 93.279, Drug Abuse and National Institute of Allergy and fentonm@niaid.nih.gov.
Addiction Research Programs, National Infectious Diseases; Notice of Name of Committee: National Advisory
Institutes of Health, HHS) Meetings Allergy and Infectious Diseases Council;
Dated: November 24, 2017. Microbiology and Infectious Diseases
Pursuant to section 10(d) of the Subcommittee.
Natasha M. Copeland,
Federal Advisory Committee Act, as Date: January 29, 2018.
Program Analyst, Office of Federal Advisory amended, notice is hereby given of Closed: 8:30 a.m. to 10:15 a.m.
Committee Policy. Agenda: To review and evaluate grant
meetings of the National Advisory
[FR Doc. 2017–25787 Filed 11–29–17; 8:45 am]
Allergy and Infectious Diseases Council. applications.
BILLING CODE 4140–01–P Place: National Institutes of Health,
The meetings will be open to the public Natcher Building, Conference Rooms
as indicated below, with attendance F1/F2, 45 Center Drive, Bethesda, MD 20892.
limited to space available. Individuals Open: 1:00 p.m. to adjournment.
DEPARTMENT OF HEALTH AND who plan to attend and need special Agenda: Reports from the Division Director
HUMAN SERVICES assistance, such as sign language and other staff.
interpretation or other reasonable Place: National Institutes of Health,
National Institutes of Health Natcher Building, Conference Rooms F1/F2,
accommodations, should notify the
Contact Person listed below in advance 45 Center Drive, Bethesda, MD 20892.
Center for Scientific Review; Notice of Contact Person: Matthew J. Fenton, Ph.D.,
Closed Meeting of the meeting. Director, Division of Extramural Activities,
The meetings will be closed to the National Institute of Allergy and Infectious
Pursuant to section 10(d) of the public in accordance with the Diseases, 5601 Fishers Lane, Rm 4F50,
Federal Advisory Committee Act, as provisions set forth in sections Bethesda, MD 20892, 301–496–7291,
amended, notice is hereby given of the 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., fentonm@niaid.nih.gov.
following meeting. as amended. The grant applications and Name of Committee: National Advisory
The meeting will be closed to the the discussions could disclose Allergy and Infectious Diseases Council;
public in accordance with the confidential trade secrets or commercial Acquired Immunodeficiency Syndrome
provisions set forth in sections property such as patentable material, Subcommittee.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., and personal information concerning Date: January 29, 2018.
as amended. The grant applications and individuals associated with the grant Closed: 8:30 a.m. to 10:15 a.m.
the discussions could disclose Agenda: To review and evaluate grant
applications, the disclosure of which applications.
confidential trade secrets or commercial would constitute a clearly unwarranted
property such as patentable material, Place: National Institutes of Health,
invasion of personal privacy. Natcher Building, Conference Room A, 45
and personal information concerning Center Drive, Bethesda, MD 20892.
individuals associated with the grant Name of Committee: National Advisory
Allergy and Infectious Diseases Council. Open: 1:00 p.m. to adjournment.
applications, the disclosure of which Date: January 29, 2018. Agenda: Program advisory discussions and
would constitute a clearly unwarranted Open: 10:30 a.m. to 11:40 a.m. reports from division staff.
invasion of personal privacy. Agenda: Report from the Institute Director. Place: National Institutes of Health,
Name of Committee: Center for Scientific Place: National Institutes of Health, Natcher Building, Conference Rooms E1/E2,
Review Special Emphasis Panel; Member Natcher Building, Conference Rooms E1/E2, 45 Center Drive, Bethesda, MD 20892.
Conflict. 45 Center Drive, Bethesda, MD 20892. Contact Person: Matthew J. Fenton, Ph.D.,
Date: December 12, 2017. Closed: 11:40 a.m. to 12:00 p.m. Director, Division of Extramural Activities,
daltland on DSKBBV9HB2PROD with NOTICES

Time: 12:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant National Institute of Allergy and Infectious
Agenda: To review and evaluate grant applications. Diseases, 5601 Fishers Lane, Rm 4F50,
applications. Place: National Institutes of Health, Bethesda, MD 20892, 301–496–7291,
Place: National Institutes of Health, 6701 Natcher Building, Conference Rooms E1/E2, fentonm@niaid.nih.gov.
Rockledge Drive, Bethesda, MD 20892 45 Center Drive, Bethesda, MD 20892. Name of Committee: National Advisory
(Telephone Conference Call). Contact Person: Matthew J. Fenton, Ph.D., Allergy and Infectious Diseases Council;
Contact Person: Mike Radtke, Ph.D., Director, Division of Extramural Activities, Allergy, Immunology and Transplantation
Scientific Review Officer, Center for National Institute of Allergy and Infectious Subcommittee.

VerDate Sep<11>2014 19:42 Nov 29, 2017 Jkt 244001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\30NON1.SGM 30NON1

Document Created: 2017-11-30 00:34:40
Document Modified: 2017-11-30 00:34:40

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 15, 2017.
FR Citation		82 FR 56834

82 FR 56834 - National Institute on Drug Abuse; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 229 (November 30, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health